BioTuesdays
Freeline Therapeutics

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

Acurx Pharmaceuticals

Maxim starts Acurx Pharma at buy; PT $12

Maxim Group initiated coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $12 price target. The stock closed at $4.89 on Nov. 26. Acurx is developing ibezapolstat, a member of an emerging new class...

Mdx Health

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...

Aura Biosciences

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

Airsculpt Technologies

SVB Leerink starts Airsculpt at OP; PT $26

SVB Leerink launched coverage of Airsculpt Technologies (NASDAQ:AIRS) with an “outperform” rating and price target of $26. The stock closed at $13.61 on Nov. 22. Airsculpt has created an innovative luxury consumer brand...

Analysts start Sonendo at buy, OW

Analyst for Stifel and Piper Sandler initiated coverage of Sonendo (NYSE:SONX) with “buy” and “overweight” ratings and prices targets of $16 and $17, respectively. The stock closed at $10.55 on Nov. 22. Sonendo is a...

Reneo Therapeutics

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

Lensar

BTIG starts LENSAR at buy; PT $15

BTIG launched coverage of LENSAR (NASDAQ:LNSR) with a “buy” rating and $15 price target. The stock closed at $7.10 on Nov. 19. LENSAR is a small-cap technology play on the fast growing laser cataract surgery market. By...

Foghorn Therapeutics

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

Minerva Surgical

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

CytomX

BTIG starts CytomX Therapeutics at buy; PT $16

BTIG initiated coverage of CytomX Therapeutics (NASDAQ:CTMX) with a “buy” rating and price target of $16. The stock closed at $7.02 on Nov. 12. CytomX is a clinical-stage biotechnology company focused on developing...

Acutes-Medical-Logo

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

T2 Biosystems Logo

AGP cuts T2 Biosystems PT to 88 cents from $1.25

Alliance Global Partners reduced its price target for T2 Biosystems (NASDAQ:TTOO) to 88 cents from $1.25 and maintained a “neutral” rating after the company reported mixed third quarter results. The stock closed at 79...

PharmaCyte Logo

HCW starts PharmaCyte Biotech at neutral

H.C. Wainwright initiated coverage of PharmaCyte Biotech (NASDAQ:PMCB) with a “neutral” rating without a price target, as “we await the FDA’s clinical hold to be lifted.” The stock closed at $2.93 on Oct. 5. “Once...

Deciphera Pharma

Stifel cuts Deciphera Pharma to hold; PT to $10 from $60

Stifel downgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “hold” from “buy” and slashed its price target to $10 from $60 after the failure of the company’s Qinlock in 2L gastrointestinal stromal tumor (GIST).  Shares...

Pliant Therapeutics

HCW starts Pliant Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2. Pliant is a clinical-stage biopharmaceutical company focused on the...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.